Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
SELLAS Life Sciences (SLS): Analyst Targets Suggest +400% Upside Potential

SELLAS Life Sciences (SLS): Analyst Targets Suggest +400% Upside Potential

Key Takeaways

  • The central $37.50 stock price target is the arithmetic mean of two verified analyst price targets — $35 and $40 — both set after the company's positive Phase 3 REGAL readout.
  • From a latest verified price near $7.50 per share, reaching $37.50 would require a gain of roughly 400%, a very large move even for a volatile clinical-stage biotech.
  • Jason McCarthy of Maxim Group raised his target to $40 from $30, while James Molloy of Alliance Global Partners holds a $35 target; both rate the shares a Buy.
  • Support comes from Phase 3 data showing lead candidate galinpepimut-S (GPS) cut the risk of death by 41% in acute myeloid leukemia (AML), plus an advancing SLS009 program.
  • The biggest risks are binary clinical and regulatory execution, dilution for a pre-revenue company, and extreme share-price swings.
  • For more context, review the company's Major News, Today's Price Move, Forecast, and Earnings pages.
  • Explore Trending AI Robots to see how AI-driven strategies are monitoring names like SLS.

Analyst Price Targets and Consensus View

SLS is the ticker for SELLAS Life Sciences Group, Inc., a New York-based, late-stage clinical biopharmaceutical company focused on cancer immunotherapy. Two current, individually attributable analyst price targets were reviewed to build the central figure used here. Maxim Group's Jason McCarthy raised his target to $40 from $30 and reiterated a Buy rating, while James Molloy of Alliance Global Partners maintains a $35 target with a Buy rating. The average analyst price target of those two figures is $37.50, rounded from the exact mean of $37.50, with a range of $35 to $40.

This is a narrow range in absolute terms but a very wide one relative to the current share price, reflecting how much analysts expect the value of the pipeline to expand if execution stays on track. The figures should be read as a calculated mean of published targets rather than an official published consensus. The bullish view centers on the pivotal REGAL data and a planned Biologics License Application (BLA) for GPS in AML; the cautious element is that even these Buy-rated analysts model success only with meaningful regulatory and funding execution risk. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

As of mid-November 2026, SLS trades near $7.50 per share, with a 52-week range of roughly $1.39 to $15.88 and a market capitalization in the vicinity of $1.5 billion. The stock has been extraordinarily volatile after the Phase 3 REGAL results, which drove a sharp rally from far lower levels. To reach $37.50, the shares would need to gain about 400% — a very large move by any conventional measure.

The path is fundamentally event-driven rather than earnings-driven. Because SELLAS is pre-revenue, the share price reflects expectations for its clinical assets, particularly GPS and SLS009 (tambiciclib), a selective CDK9 (cyclin-dependent kinase 9) inhibitor. Progress on regulatory discussions, additional data readouts, and financing all matter more than quarterly profit in the near term. From what I see, this makes the setup particularly sensitive to upcoming catalysts.

What Could Support a Move Toward the Target

  • Positive Phase 3 data. GPS cut the risk of death by 41% in the REGAL trial, with a hazard ratio of 0.59, a two-sided p-value of 0.035, and median overall survival of 24.0 months versus 14.7 months for the control arm.
  • Regulatory path. Management plans to meet with the FDA and prepare a BLA for GPS in the first half of 2027, a catalyst analysts cite in their higher targets.
  • Second asset. SLS009 has shown encouraging response rates in relapsed or resistant AML, with additional data expected at the American Society of Hematology meeting in December.
  • Balance sheet. The company reported roughly $134.7 million in cash and equivalents at the end of September 2026, providing runway toward key milestones.

What Could Prevent the Target From Being Reached

  • Regulatory risk. A positive trial does not guarantee FDA approval; the filing, review, and labeling process carries material uncertainty.
  • Data maturity. More detailed REGAL data is still expected at a medical conference, and the durability and breadth of the benefit will be scrutinized.
  • Dilution. As a pre-revenue company with a small team, SELLAS may need additional equity financing, which can pressure the share price.
  • Valuation and volatility. After a massive rally, the stock's wide intraday swings and a notable bid-ask spread make the current market price itself unstable.
  • Competition. The AML treatment landscape is active, with competing and emerging therapies that could affect commercial prospects.

Technical Levels and Market Structure

The long-term structure is defined by a 52-week low near $1.39 and a 52-week high near $15.88, the latter reached during the post-readout surge before a pullback toward current levels. The $15.88 area now represents a notable resistance level, while the recent intraday low around $7.24 serves as a nearer-term support level. Because the stock is thinly valued on fundamentals and driven by binary news, these levels can shift quickly and should be viewed as reference zones rather than precise floors or ceilings.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of roughly 12 months, though biotech targets are frequently tied to specific events rather than a strict calendar. Key items to monitor include the FDA meeting and BLA filing timeline for GPS, detailed REGAL data at an upcoming medical conference, SLS009 results at the December hematology meeting, any new financing, and revisions to analyst targets. Each of these could materially shift the probability of approaching the $37.50 level. I’m watching this closely as the timeline unfolds.

Final Assessment

The $37.50 central target is the mean of two current Buy-rated analyst targets, $35 and $40, and sits far above the stock's recent price near $7.50 — a gap of roughly 400%. The bull case rests on validated Phase 3 survival data for GPS, a planned FDA filing, and a promising second asset, while the bear case centers on regulatory uncertainty, financing risk, and extreme volatility. With only two covering analysts and a very wide implied upside, the figure is best understood as a directional expression of pipeline value rather than a precise forecast. Investors should watch the regulatory timeline, follow-on data, and balance-sheet position before drawing conclusions.

AI Tools for Tracking Volatile Names

In my view, tools like Tickeron’s AI Daily Buy/Sell Signals can add a useful layer when following event-driven biotechs. They apply artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. For a name like SLS, this kind of systematic monitoring helps surface changes that might otherwise require constant manual review, allowing traders to stay aligned with their own analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SLS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


SLS's RSI Oscillator stoops into oversold zone

The RSI Indicator for SLS moved into overbought territory on November 16, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 240 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

SLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SLS as a result. In 72 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for SLS turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for SLS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.352) is normal, around the industry mean (3.586). P/E Ratio (-38.273) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Industry
Biotechnology
Address
7 Times Square
Phone
+1 646 200-5278
Employees
13
Web
https://www.sellaslifesciences.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.